TKNO ALPHA TEKNOVA INC

Teknova to Participate in Upcoming Investor Conference

Teknova to Participate in Upcoming Investor Conference

HOLLISTER, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will present and host individual and small group meetings at the following upcoming investor conference:

William Blair 43rd Annual Growth Stock Conference

June 6 - 8, 2023

Chicago, IL

Stephen Gunstream, Teknova’s President and Chief Executive Officer, and Matt Lowell, Teknova’s Chief Financial Officer, will present at 4:20 p.m. ET, on Tuesday, June 6, 2023. Gunstream and Lowell plan to discuss Company highlights, its product portfolio, market trends, key growth drivers, and long-term market opportunities.

A live audio webcast of this presentation may be accessed from the Investor Relations section of the Company’s website: . Webcasts are available on the Company’s website for approximately 90 days after each event.

ABOUT TEKNOVA  

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

 



Investor Contacts
Matt Lowell
Chief Financial Officer
 
 

Sara Michelmore
MacDougall Advisors
 
 

Media Contact
Jennifer Henry  
Senior Vice President, Marketing 
   
  
EN
25/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TEKNOVA INC

 PRESS RELEASE

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern T...

 PRESS RELEASE

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation...

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies Innovative product line is purpose-built to streamline the manufacture of allogeneic cell therapies. Available exclusively from Teknova starting today. HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx’s PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, ...

 PRESS RELEASE

Teknova and Pluristyx Announce Collaboration to Streamline the Manufac...

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx’s Novel PluriFreeze™ Cryopreservation System HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic...

 PRESS RELEASE

Teknova Reports Fourth Quarter and Full Year 2024 Financial Results

Teknova Reports Fourth Quarter and Full Year 2024 Financial Results Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides 2025 revenue guidance of $39-42 million HOLLISTER, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announce...

 PRESS RELEASE

Teknova to Report Fourth Quarter and Full Year 2024 Financial Results ...

Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market. Teknova will host a webcast and conference call on Tuesday, March 4,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch